Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based clinical-stage biopharmaceutical firm Kite Pharma has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, for the devlopment of new cancer immunotherapy products.
Subscribe to our email newsletter
Recently, the company has also leased a clinical manufacturing facility in Santa Monica, California.
The expansion of the manufacturing capabilities will help the firm to support the development and commercialization of chimeric antigen receptor (CAR) and T cell receptor (TCR) cancer immunotherapy products.
Both the facilities will support the planned clinical trials of the company’s product candidates as well as prepare for the scheduled commercial launch and supply of its lead product candidate, KTE-C19, in 2017.
Kite Pharma president and chief executive officer Arie Belldegrun said: "We are committed to the rapid advancement of KTE-C19, which has the potential to address the significant, unmet needs of patients with aggressive, refractory B cell lymphomas and leukemias.
"We are initiating pivotal studies for KTE-C19 in multiple indications and believe our new facilities will help ensure the timely completion of these studies as well as our commercial launch."
Upon completion, the 18,000ft² Santa Monica facility will provide space for clinical manufacturing, research and development, and offices
Additionally, the company intends to continue to use its contract manufacturer to support clinical trials of eACT based product candidates.
Under the lease agreement, the company has an option to expand the 44,500ft² El Segundo facility for an additional 17,000ft² until 01 July 2017.